Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Nektar Therapeutics (NKTR) stock is taking a beating on Friday following the release of poor Phase 2 clinical trial data.

The post Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today? appeared first on InvestorPlace.

• Buy This $5 Stock BEFORE This Apple Project Goes Live
• The Best $1 Investment You Can Make Today
• It doesn’t matter if you have $500 or $5 million. Do this now.
• Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It